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ABSTRACT

In the present study, we investigated the involvement of Chmp1 (Chromatin Modifying
Protein 1/Charged Multivesicular body Protein 1) in the development of mouse
pancreatic acinar tumor cell line. CRL 2151 cell line was transfected with Chmp1/CS2
vector to compare growth, morphology and expression of Chmp1, p53 and pp53 (ser
37) with control-transfected cells. CRL 2151 cells were treated with all-trans retinoic
acid (ATRA) to compare growth, morphology and expression of Chmp1 and p53 with
control-treated cells. Strabismus was used as control. Results showed inhibition of
growth but no morphological change in transfected cells. Western blot analysis showed
that Chmp1 transfection upregulated the expression of p53, pp53 and Stbm temporarily.
Treatment of cells with ATRA did not inhibit growth or show morphological change.
However, Western blot analysis demonstrated the upregulation of Chmp1, p53 and
Stbm proteins. Microarray analysis of samples transfected with Chmp1 or treated with
retinoic acid was done to determine if the same set of genes will be regulated. The proapoptotic genes Bad and Bak are among the genes up-regulated. Cell division cycle
protein, Cdca7, was among the genes down-regulated. Results from Western blot
analysis confirmed the expression of Bad and Bak genes. Taken together, these results
suggest that Chmp1 functions in the suppression of pancreatic tumor by the retinoic
acid signaling pathway.
Key Words: CRL 2151, Chmp1, Stbm, p53, Bad, Bak, Cdca7, ATRA.
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CHAPTER 1

INTRODUCTION

Chmp1 (Chromatin Modifying Protein 1/Charged Multivesicular body Protein 1) is a
novel protein found to be widely conserved across eukaryotes [1, 2]. It is localized in the
nucleus as well as in the cytoplasm. It is found in the interphase nuclear matrix and
mitotic chromosome scaffold affecting chromatin structure and cell cycle progression [24]. In the cytoplasm, it is involved in protein sorting to the multivesicular body [1, 4-7].
Chmp1 therefore plays a dual function of nuclear gene regulation and membrane
trafficking.
Very few studies have so far been done on Chmp1. One of the studies reported
that Chmp1 localizes to early and late endosomes in HEK 293 (human embryonic
kidney) and COS7 (African green monkey kidney) cell lines [1]. This study further
showed that it interacts with SKD1/VPS4 (vacuolar protein sorting 4b) in sorting proteins
into multivesicular bodies. Another investigation by Stauffer et al, (2001) identified
Chmp1 as a binding partner of Pcl (PcG polycomblike) proteins in HEK 293 cell line.
The PcG (polycomb group) are proteins involved in gene silencing. In addition, they
reported that Chmp1 affects nuclear structure by increasing nuclear DNA concentration
through chromatin condensation. It was shown to also affect DNA replication by
arresting cells in S-phase of the cell cycle.
A closely related protein family of Chmp1 (Chmp1b) was studied by Reid et al,
(2004). They identified Chmp1b as a binding partner of Spastin in COS7 and PC12
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(Pheochromocytoma) cell lines. Spastin is a protein involved in hereditary spastic
paraplegia (HSP), a neurological disorder characterized by progressive weakness and
stiffness of the leg. They found that the expression of Chmp1b prevented the
development of the abnormal phenotype associated with the expression of mutated
spastin, suggesting a regulatory role for Chmp1b. Furthermore, they suggested that
Chmp1b interacted with Spastin to play a role in membrane trafficking. Interestingly, a
homolog of Chmp1 was identified in plant. This homolog, SAL1 (supernumerary
aleurone layers 1), was studied in maize by Shen et al, (2003). They found SAL1 to be
involved in regulating the formation of aleurone cell layer in maize grains. Failure to
target internalized membranes to lytic vacuoles in grain with mutated sal1 resulted into
more layers of aleurone cells in defective maize endosperm. These results suggest that
SAL1 may be involved in membrane trafficking and the lack of this function may
contribute to abnormal growth.
Even though Chmp1 has been implicated in cell cycle progression, chromatin
structure, gene silencing and membrane trafficking, its function in vertebrate
development and in tumor formation is not yet known.
Our lab identified Chmp1 as one of Strabismus (Stbm) binding proteins from
yeast two-hybrid screen. Strabismus is known to function in the Planar Cell Polarity
(PCP) signaling pathway, modulating convergent extension movement in zebrafish [8].
Mis-expression of Chmp1 produced convergent extension movement defects in
zebrafish similar to its binding partner, Stbm [Park et al, in preparation]. However unlike
Stbm, Chmp1 mis-regulation (either by microinjecting embryo with Chmp1 mRNA or
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Morpholino) induced hyperplasia (Figure 1), an abnormal cell growth, in zebrafish
indicating that Chmp1 may function in tumorigenesis [Park et al, in preparation].

A. 2-day old

B

C

B

C

A. 2½-day old

Figure 1: Induction of hyperplasia in zebrafish by Chmp1. Embryo was microinjected with Chmp1 mRNA,
mis-regulation of Chmp1 induced abnormal growth. The embryos on the top are zebrafish at 2 days old;
the images on the bottom are the same fish at 2½ days (Courtesy of Dr. Park’s lab).

To test this hypothesis, a human cancer profiling array from CLONTECH cancer
Profiling Array II was screened to measure Chmp1 mRNA level. Also, a human cancer
tissue array was screened to quantify Chmp1 protein level. Results obtained from the
profiling array showed differential expression of Chmp1 between the various tumors and
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their corresponding normal tissues. The pancreas showed the greatest differential
expression between the tumors and their normal tissues (Figure 2).

Densitometric analysis
Chmp1
Chmp1/ubi density

Ubi

Figure 2: Cancer profiling array of cDNAs from various pancreatic tumors and their corresponding normal
tissues. The left shows control Ubiquitin mRNA expression from various normal (N) and pancreatic tumor
(T) samples. The array on the right is the same array showing Chmp1 mRNA level. The graph is a
densitometric analysis of the results. This shows the dramatic repression of Chmp1 in pancreatic tumor
(Courtesy of Dr Park’s lab).

Among the pancreatic cancer tissues investigated, pancreatic acinar tumor is the
only tumor which showed almost no expression of Chmp1 protein. Chmp1 protein
expression within the pancreatic acinar tumor cells was greatly reduced even though its
expression in the connective tissue cells was not reduced (Figure 3).

5

pancreas normal tissue

pancreas cancer tissue

acinar cells

acinar cells

connective tissue

Figure 3: Chmp1 antibody staining. Normal and tumor cells of the pancreas were immunostained with
Chmp1 antibody. Arrows point to Chmp1 protein (dark brown stain) within the nucleus of the cells. Chmp1
protein expression within the pancreatic acinar cells (right) is greatly reduced even though its expression
in the connective tissue cells is not reduced (Courtesy of Dr. Park’s lab).

On the basis of these results, we decided to investigate the role that Chmp1 may
play in the development of pancreatic acinar tumors. Our lab is the first to investigate
the involvement of Chmp1 in convergent extension movement and the induction of
hyperplasia in vertebrate development. It is also the first to investigate the expression of
Chmp1 during cancer development.

6
Retinoids are natural and synthetic derivatives of vitamin A (retinol). They exert
dramatic effects on cell death and differentiation in human tumor cells, and in vertebrate
embryogenesis; modulating differentiation, proliferation and apoptosis in both normal
and neoplastic tissues [9-15]. Several investigators have demonstrated that all-trans
retinoic acid (ATRA) inhibits growth of pancreatic cancer cells both in vivo and in vitro
[9, 13, 14, 16, 17]. This inhibition is thought to occur in part through the p53, a tumor
suppressor, pathway [18].
Pancreatic cancer is one of the rarest cancers and yet it is the fifth leading cause
of cancer death in the United States, with an annual of about 28,200 diagnoses and
death [19-21]. The mortality rate is the highest among cancer types, in part because of
the asymptomatic nature of the disease in early stages [21]. It affects men twice as
frequently as women and is more likely to develop after the age of 40 [22]. Pancreatic
cancer risks increase with chronic pancreatitis, diabetes mellitus, genetic factors (more
common in African Americans than Caucasians), smoking, excess alcohol consumption,
high-fat diets, and exposure to industrial chemicals such as urea, naphthalene or
benzidine. Symptoms include weight loss, abdominal pain, and nausea, loss of appetite,
itching, jaundice, and constipation. Because its symptoms mimic many other common
health problems [22], it often goes undetected until it is too late to treat effectively.
Pancreatic exocrine tumors are more common than the tumors from the
endocrine. The majority of the exocrine tumors are adenocarcinomas, and nearly all of
these are ductal adenocarcinomas. Pancreatic acinar cell carcinomas are rare
neoplasms of the exocrine pancreas, comprising less than 1% of primary pancreatic
tumors[23, 24]. They are distinct from the more common pancreatic ductal
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adenocarcinomas. The prognosis in adults is poor, with the majority of patients showing
evidence of metastatic disease either at or subsequent to diagnosis [23, 25-28] ; and a
reported mean survival of 18 months[23, 29, 30].
Pancreatic cancer is the only cancer with a diagnosis rate less than the mortality
rate. More studies are therefore needed to better understand and address the cellular
mechanisms and pathways by which this cancer develops. In the present investigation,
we hypothesized that Chmp1 may function through retinoic acid signaling to inhibit cell
growth by activating p53 [18].

PURPOSE
Our long term goal is to identify the potential pathways by which Chmp1 may function in
pancreatic tumors. The first purpose was to determine how Chmp1 over-expression or
gain of function through transfection may affect the growth of CRL2151, a pancreatic
acinar tumor cell line. Morphology of cells was observed under the microscope and the
number was counted. Based on the report from several investigators that retinoic acid
inhibits growth of pancreatic cancer cells, we chose to treat CRL2151 cells with ATRA.
The second purpose was to investigate growth inhibition, morphological changes and
expression level of Chmp1, p53 and Stbm in CRL2151 cells after treatment with ATRA.
We chose p53 on the basis of report of studies that indicates p53 to be expressed
during cancer growth inhibition and its stability by phosphorylated p53 (pp53). Stbm was
chosen as a control on the basis of it being a binding partner of Chmp1 in our previous
investigation. The third purpose was to determine if Chmp1 gain of function or over
expression would induce the up-regulation of p53 in CRL2151 cells. Fourthly, we set out
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to confirm that Chmp1 functions through retinoic acid by activating p53. In this case we
carried out microarray analysis of samples transfected with Chmp1 or treated with
retinoic acid to determine if the same set of genes will be regulated. The rationale for
this research was that if the function of Chmp1 in pancreatic tumor is known, Chmp1
may serve as a pharmacological target protein for treating pancreatic tumors.

SPECIFIC AIMS
The objective of this study was to determine the role of Chmp1 during the development
of pancreatic acinar tumor. The hypothesis is that Chmp1 may function through retinoic
acid signaling to inhibit cell growth by activating p53. In this study, we determine the
effect of exogenous Chmp1 and ATRA on growth, morphology and expression of
Chmp1, p53, pp53 and Stbm of CRL2151 cell line. We also determine the genes
expressed by these two treatments.

Specific Aim 1:
To determine the effect of Chmp1 on the growth and morphology of CRL2151. In
this case we transfected cells with Chmp1/CS2 vector and CS2 vector (control)
for 1, 2, 3 and 4 days. Transfection with Stbm/CS2 vector also served as control.
Photos of cells were taken, followed by cell counting and statistical analysis of
cell numbers.
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Hypothesis:
We hypothesized that Chmp1 would induce a decrease in cell growth and cause
morphologyical changes.

Specific Aim 2:
To determine the effect of ATRA on cell growth, morphology and the expression
of Chmp1, p53 and Stbm in CRL2151 cells. Cells were treated with ATRA in
Dimethyl Sulfoxide (DMSO) for 1, 2, 3 and 4 days.

Photos of cells were taken.

Cells were trypsinized for cell count and lysed for Western blot on days 1, 2, 3
and 4. Cell numbers were statistically analysed and alterations in the expression
of Chmp1, p53 and Stbm were evaluated by densitometry method.

Hypothesis:
We hypothesized that ATRA will induce a decrease in cell growth and cause
morphological changes in cells, with a corresponding increase in the expression
of Chmp1 accompanied by increase in the expression of p53.

Specific Aim 3:
To determine the level of expression of Chmp1, p53, pp53 and Stbm in CRL2151
cells transfected with Chmp1. Cells were transfected with Chmp1/CS2 and CS2
vectors for 1, 2 and 3 days. Transfection of cells with Stbm/CS2 vector also
served as control. Cells were trypsinized and lysed for Western blot. Alterations
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in the expression of Chmp1, p53, pp53 and Stbm were evaluated by
densitometry.

Hypothesis:
Our hypothesis was that the level of Chmp1 expression will increase with an
accompanied increase in p53 and pp53 expression.

Specific Aim 4:
To determine that Chmp1 functions through retinoic acid by activating p53. In this
case we expect that the same genes will be up or down regulated when
CRL2151 cells are transfected with Chmp1 or treated with ATRA. To examine
this possibility, we treated cells with ATRA and also transfected cells with
Chmp1. Cells were trypsinized and total cellular RNA was prepared using Tris
Reagent. The gene expression level was determined by microarray analysis.
Gene expression was confirmed by Western-blot. Expression of proteins was
evaluated by densitometry.

Hypothesis:
We hypothesized that similar genes will be expressed when CRL2151 cells are
treated with ATRA and transfected with Chmp1.
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CHAPTER 2

REVIEW OF THE LITERATURE

INTRODUCTION
This chapter presents a review of the relevant literatures concerning the present study.
Specifically, the following areas will be addressed: 1) the potential functions of Chmp1
and 2) the role of retinoids and their inhibition in the growth of cancers.

The potential functions of Chmp1
Chmp1 is a novel protein and a member of the Chmp protein family. It is known to
contain a predicted bipartite nuclear localization signal. Also, it is reported to distribute to
the nuclear matrix and to the cytoplasm [2]. In the nucleus, Chmp1 is localized in the
nuclear matrix of HeLa (human epithelial carcinoma) cells where it affects chromatin
structure and cell-cycle progression [2]. Chmp1 also functions as a member of a newly
defined family of vesicle trafficking proteins in the cytoplasm in yeast [1, 4-7].
A zebrafish protein was identified from yeast two-hybrid screen, and named as
SAP7 (Strabismus Associated Protein 7) in our lab. This protein was found to be a
homolog of human Chmp1. The interaction between Chmp1 and Strabismus (Stbm) has
also been confirmed by co-immunoprecipitation in our lab. Strabismus is involved in
convergent extension movements in vertebrate [8, 31, 32]. Chmp1 also functioned in
embryo development similar to Strabismus, and it induced hyperplasia when misregulated in zebrafish [Park et. al., in preparation] (Figure 1).
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Several investigators have reported that the Chmp family of proteins are
components of endosomal sorting complex required for transport-III (ESCRT-III)[3, 4, 7,
33, 34]. ESCRT-III is a membrane-associated protein complex that mediate the sorting
of cargoes to the multivesicular body. This is why Chmp are referred to as Charged
Multivesicular body Proteins, in addition to being called Chromatin Modifying Proteins.
The Chmp proteins were originally identified in yeast genetic screens[35, 36].
Subsequent studies have identified at least one human homolog for each protein[37],
indicating that they are conserved across eukaryotes. These proteins are recruited to
sites of multivesicular body protein sorting and vesicle formation[34].
Proteins targeted for lysosomal degradation are sorted into vesicles that bud into
late endosomal compartments called multivesicular bodies (MVB). Once formed,
multivesicular bodies can undergo several different fates. They may either serve as
long-term storage compartments, fusing with lysosomes to deliver the internal vesicles
and their contents for degradation. Or they may fuse with the plasma membrane to
release the vesicles as extracellular “exosomes.”
important

biological

processes,

including

MVB function in a number of

receptor

down-regulation,

antigen

presentation, intercellular communication, and development[35, 38-40]. Vesicle
trafficking therefore provides communication and transport between membrane-bound
compartments involved in biosynthesis, degradation and cell surface signaling. Also, a
number of enveloped RNA viruses, including HIV-1, are reported to usurp cellular
proteins involved in MVB biogenesis to facilitate virus budding [37, 41].
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Chmp1, like most other members of the Chmp family, is implicated in
multivesicular body (MVB) formation. In this process it is reported to localize to early
and late endosomes physically interacting with SKD1/VPS4 (vacuolar protein sorting
4b), a highly conserved protein directly linked to multivesicular body sorting in both
human and yeast[33, 42-45].
Investigation by Stauffer, et al., (2001) revealed other important functions of
Chmp1. They reported that Chmp1 has potent affects on nuclear structure by increasing
nuclear DNA concentration through chromatin condensation. Also Chmp1 affects DNA
replication by arresting cells in S-phase of the cell cycle. Furthermore they identified
Chmp1 as a partner of the PcG protein polycomblike (Pcl). The PcG (polycomb group)
consists of a large, structurally diverse set of nuclear proteins, which functions both to
select target genes and regulate their transcription in epigenetic modifications. The PcG
proteins are involved in maintenance of the silenced state of several developmentally
regulated genes. When Chmp1 is over-expressed, it is reported to encapsulate proteins
in the Polycomb complex and localize them to visibly condensed chromatin, suggesting
that Chmp1 may function with PcG in gene silencing [2].
Closely related family of Chmp1, Chmp1b, is identified as a binding partner of
Spastin in COS7(African green monkey kidney) and PC12(Pheochromocytoma) cell
lines [3]. Mutations in spastin are responsible for hereditary spastic paraplegia (HSP), a
group of inherited disorders characterized by progressive weakness and stiffness of the
legs. Expression of Chmp1b prevented the development of this abnormal phenotype
associated with the expression of mutated spastin, suggesting a regulatory role for
Chmp1b. Also, Chmp1b interacted with Spastin to play a role in membrane trafficking.
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Another homolog of Chmp1, SAL1 (supernumerary aleurone layers 1), is identified in
maize [6]. SAL1 protein is involved in the regulation of aleurone cell (a component of the
endosperm in cereal grains) formation in maize grains. The failure to target internalized
membranes to lytic vacuoles in grain carrying mutated sal1 caused more layers of
aleurone cells in defective maize endosperm, suggesting that SAL1 May be involved in
membrane trafficking.
Overall, reports from the few studies on Chmp1 suggest that Chmp1 may
function in several pathways which involve gene regulation and membrane trafficking.
Even though Chmp1 has been implicated in cell cycle progression, chromatin structure,
gene silencing and membrane trafficking, the function of Chmp1 in vertebrate
development and in tumor formation has not been studied.

Summary
Chmp1 is a novel protein and a member of the Chmp protein family. Chmp1 is
conserved across eukaryotes. It functions in gene expression and silencing. It also
functions in cell-cycle progression. Chmp1 induces hyperplasia in zebrafish and is
involved in convergent extension movement in embryogenesis. It is involved in protein
sorting to the multivesicular body. Its function in tumors is yet unknown.

Retinoids and their inhibition in the growth of cancers
Retinoids belong to a class of molecules that are structurally related to vitamin A. They
have potent anti-proliferative and differentiating effects on a variety of normal and
neoplastic tissues [9, 10, 12-15]. They also play a crucial role in embryogenic
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development [10, 12, 46-48]. They are therapeutically effective in the treatment of some
cancers, skin disorders such as acne, psoriasis and photoaging, and have the potential
for protecting certain cells from particular injury [49]. Retinoids have the ability to arrest
growth in carcinoma cells, melanoma, lymphoma, neuroblastoma, and embryonic stem
cells [50]. The potential role of different types of retinoids for pancreatic cancer in vitro
and in vivo has been reported [9, 16, 51, 52], with several investigators demonstrating
that all-trans retinoic acid (ATRA) inhibits growth of human pancreatic-cancer cells in
vitro and in vivo [9, 16].
Cancers of the pancreas can be grouped according to where in the pancreas the
cancer is or according to the type of cell the cancer has originated from. It can occur in
the head, body or tail of the pancreas. The vast majority of cancers of the pancreas are
the exocrine type, and most of these are adenocarcinomas, nearly all are ductal
adenocarcinomas. The ducts carry pancreatic digestive juices to the main pancreatic
duct and the duodenum. The rarer types of exocrine pancreatic cancers are cystic
tumors, cancer of the acinar cells and sarcomas. The acinar cells are the cells at the
ends of the ducts that produce the pancreatic juices.
Most of the effects of retinoids in pancreatic cancers are due to the activation of
the retinoic acid receptors. This triggers transcriptional events that lead either to
transcriptional activation or repression of retinoid-controlled genes. These biological
effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) and
retinoid X receptors (RXRs). Each receptor family consists of three receptor subtypes ( ,
, ) encoded by independent genes [50, 53, 54]. Modulation of gene expression occurs
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through binding of ligand-activated RAR/RXR to retinoid responsive elements located in
the regulatory regions of target genes [47, 55-62].
The inhibition of cancer cells by retinoids is thought to occur through the p53
pathway [18]. Inhibition may occur by means of G1-phase cell-cycle arrest resulting
from the prevention of RB (retinoblastoma) phosphorylation and the up-regulation of
p21 and p27, as well as the induction of apoptosis [17].
The p53 protein is a tumor-surpressor of cells that prevents their entry into the
route to carcinogenesis[63]. It is a multifunctional protein that can modulate genes
involved in the control of cell growth and apoptosis [64]. In response to cellular stress
such as DNA damage, hypoxia and oncogenic signals, p53 functions in cell cycle
progression checkpoints arrests[63, 65]. The protein p53 induces apoptosis (a type of
programmed cell death) by target gene regulation and by translocating to the
mitochondria to promote the release of cytochrome c [65, 66]. Commitment of cells to
apoptosis is controlled largely by the interaction between members of the Bcl-2 protein
family. Activated p53 tansactivates pro-apoptotic genes such as Bad and Bak [67]. Bad
and Bak in turn trigger apoptosis when they bind to Bcl-2 or its homologs and block their
antiapoptotic activity[67-71].
Several investigations on the effect of retinoids on pancreatic tumor cells have
been done. It is not known if Chmp1 expression occurs when pancreatic tumor cells are
treated with retinoids.
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Summary
Retinoids modulate cellular proliferation and differentiation in a variety of tissues of the
adult organism as well as during embryogenesis and development. Studies have been
done to investigate RA-mediated growth inhibition and apoptosis on some pancreatic
cancer cells. However no study has investigated whether Chmp1 functions through RA
signaling.
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CHAPTER 3

CHMP1 IS IMPLICATED IN THE DEVELOPMENT OF PANCREATIC TUMOR VIA
THE RETINOIC ACID SIGNALING PATHWAY

J. Akinsete and M. Park
Department of Biological sciences and Department of Biochemistry,
Marshall University

ABSTRACT
In the present study, we investigated the involvement of Chmp1 in the development of
mouse pancreatic acinar tumor cell line. CRL 2151 cell line was transfected with
Chmp1/CS2 vector to compare growth, morphology and expression of Chmp1, p53 and
pp53 (ser 37) with control-transfected cells. CRL 2151 cells were treated with all-trans
retinoic acid (ATRA) to compare growth, morphology and expression of Chmp1 and p53
with control- treated cells. Strabismus was used as control. Results showed inhibition of
growth but no morphological change in transfected cells. Western blot analysis showed
that Chmp1 transfection upregulated the expression of p53, pp53 and Stbm temporarily.
Treatment of cells with ATRA did not inhibit growth or show morphological change.
However, Western blot analysis demonstrated the upregulation of Chmp1, p53 and
Stbm proteins. Microarray analysis of samples transfected with Chmp1 or treated with
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retinoic acid was done to determine if the same set of genes will be regulated. The proapoptotic genes Bad and Bak are among the genes up-regulated. Cell division cycle
protein, Cdca7, was among the genes down-regulated. Results from Western blot
analysis confirmed the expression of Bad and Bak genes. Taken together, these results
suggest that Chmp1 functions in the suppression of pancreatic tumor by the retinoic
acid signaling pathway.
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INTRODUCTION
Pancreatic cancer is the fifth leading cause of cancer death in North America [72]. It is
second only to colon cancer as a cause of death from gastrointestinal malignancy, and
affects men twice as frequently as women with more possibility of developing after the
age of 40 [22]. It is the only cancer with a diagnosis rate less than the mortality rate.
With resection surgery, radiotherapy and conventional chemotherapy, the prognosis of
advanced pancreatic cancer has not recorded any significant improvement over the last
30 years, showing a 5-year survival rate of less than 5% [73]. However, several
investigators have demonstrated that all-trans retinoic acid (ATRA) inhibits growth of
human pancreatic-cancer cells in vitro and in vivo [9, 16].
Retinoids are vitamin A derivatives, used effectively in the therapeutic treatment
of some cancers[9, 49]. Their effects on both normal and cancer cells include
modulations of differentiation, proliferation and apoptosis [10, 15]. RARs and RXRs are
the nuclear receptors of retinoids. They function as transcription factors modulating the
activity of several target genes [10, 55].
Albrechtsson et al., (2002) studied the expression of retinoic acid receptors
(RAR) in pancreatic cancer cells and the effect of three different retinoids on the cell
number in vitro. They reported a decrease in cell number to high concentration of RA
and the expression of two or more subtypes of RAR in all pancreatic cell lines
investigated. Bold et al., (1996) studied the effect of retinoic acid on the growth of both
exocrine and endocrine pancreatic cancer cell lines. The growth of all tumor cell lines
was inhibited by retinoic acid. In their own investigation, Rosewicz et al., (1995) found a
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time-and dose-dependent growth inhibition in pancreatic carcinoma cells resulting from
retinoid treatment. There was expression of retinoid receptors and induction of
differentiation in cells. Also the effect of TAC-101, a novel retinoid, was studied on 4
human pancreatic-cancer cell lines by Fujimoto et al., (1999). It was reported that TAC101 inhibits the growth of certain pancreatic cancer cells by means of G1-phase cell
cycle arrest due to the reduction of RB phosphorylation and the up-regulation of p21
and p27. It also induces apoptosis.
Another investigation involving retinoic acid-responsive protein was carried out
by Kaiser et al., (1999). They identified the kinesin-related novel protein HsEg5 as an
all-trans-retinoic acid (ATRA)-responsive gene in pancreatic carcinoma cells, mediating
growth inhibition. The protein HsEg5 was found to play an essential role in spindle
assembly and spindle function, resulting in a delayed progression through mitosis.
Even though various studies have demonstrated that retinoids inhibit the growth
of pancreatic cancer cells, there is need for more studies that will provide a conceptual
framework to identify novel therapeutic target proteins.
Chmp1 is a novel protein conserved in both complex and simple eukaryotes [2].
Howard et al., (2001) reported this protein to early and late endosomes in African green
monkey kidney (COS7) and human embryonic kidney (HEK) cells. It was also found to
physically interact with SKD1/VPS4, a highly conserved protein linked to multivesicular
body sorting in yeast. They found Chmp1 overexpression to dilate endosomal
compartments. Investigation of Chmp1 in HEK 293 cell line by Stauffer et al., (2001)
also showed that when overexpressed, Chmp1 localizes to regions of condensed
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chromatin. It recruits a polycomb group (PcG) protein to the condensed chromatin and
can cooperate with co-expressed vertebrate PcG protein polycomblike (Pcl). In addition,
Chmp1 has potent effects on nuclear structure and DNA replication. Their results
suggest Chmp1 plays a role in stable gene silencing and DNA regulation.
Investigation from our lab showed that Chmp1 and its associated protein
(Strabismus) produced convergent extension movement defects when overexpressed in
zebrafish (Figure 1). It was also observed that Chmp1 induces hyperplasia, indicating
Chmp1 may function in tumor formation [Park et al., in preparation]. To test this
hypothesis, human cancer profiling array was screened to measure Chmp1 mRNA
level. Human cancer tissue array was also screened to quantify Chmp1 protein level.
Results showed differential expression of Chmp1 between the various tumors and their
corresponding normal tissues. Interestingly, Chmp1 mRNA level was dramatically
down-regulated in pancreatic tumor compared to the normal tissue (Figure 2). Among
the pancreatic cancer tissues investigated, pancreatic acinar cancer cell is the only cell
which showed almost no expression of Chmp1 protein (Figure 3).
The objective of this study was to investigate the molecular function of Chmp1 in
the development of pancreatic tumors. We hypothesized that Chmp1 may function
through retinoic acid signaling to inhibit cell growth by activating p53 in pancreatic
cancer cells. In this study we investigated the effect of Chmp1 on the growth of
CRL2151, a pancreatic acinar tumor cell line. Our results indicate that Chmp1 may
function as a tumor suppressor in pancreatic tumors downstream of retinoic acid
signaling pathway. Therefore, in addition to the reports that Chmp1 is involved in
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nuclear gene regulation and cell cycle progression [2, 4], suggesting that it functions in
DNA transcription and cell growth, Chmp1 may also function in tumor suppression.
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MATERIALS AND METHODS
Chemicals
All-trans-Retinoic acid (ATRA) was obtained from Sigma. It was dissolved in Dimethyl
Sulfoxide (DMSO, Fisher) at a concentration of 20µM prior to use.
Cell line and Cell Culture Condition
Mouse pancreatic acinar tumor cell line, CRL2151, was obtained from ATCC (America
Type Culture Collection). Cells were maintained in HYQ Dulbecco’s Modified Eagle’s
(DME) High glucose medium plus10% FBS and antibiotics (10000 units/ml penicillin G
sodium and 10000 µg/ml streptomycin sulfate in 0.85% saline) at 37°C in a humidified
atmosphere composed of 95% air and 5% CO2.

Cell Transfection
Cultured cells were harvested by trypsin digestion and seeded at 800,000cells/10cm
plate in DME High glucose medium with 10% FBS for 24 hr. Human Chmp1 and Stbm
genes were each previously cloned into CS2 vector containing CMV and SP6
promoters. The constructs were named Chmp1/CS2 and Stbm/CS2. CRL2151 cells
were transfected with 5µg of Chmp1/CS2 or Stbm/CS2 vector in a 10cm plate, using
Lipofectamine™ Reagent (Invitrogen). Cells were also transfected with CS2 vector only.
Both Stbm/CS2 and CS2 transfections served as controls. The transfected cells were
incubated for 1, 2, 3 and 4 days. Photos were taken from plates daily using Leica
DMI6000B inverted microscope attached to DFC camera to determine cell density and

25
morphology. After pictures were taken, cells were trypsinized for cell count using Phase
Hemacytometer (Hausser Scientific). Cell lysis was done for Western blot analysis.

Cell Growth Assay with ATRA treatment
Cultured cells were harvested by trypsin digestion and seeded at 300,000cells/10cm
plate in the DME High glucose medium with 10% FBS for 24 hr. Cell medium was
replaced with 20µM ATRA or DMSO (control) in 10% FBS DME High glucose medium
(1:1000), and incubated for 1, 2, 3 and 4 days. Photos were taken from plates daily
using Leica DMI6000B inverted microscope attached to DFC camera to determine cell
density and morphology. Thereafter, ATRA-treated and DMSO-treated plates were
trypsinized for cell count using Phase Hemacytometer (Hausser Scientific). Cells were
then lysed for Western blot analysis.

Western-blot Assay
Cells were harvested and lysed in ice-cold RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1 tablet of
Protease Inhibitor Cocktail/ 10mL RIPA buffer. Protein expressions were quantified by
using the BCA Protein Assay kit (EMD Biosciences, Inc. Darmstadt, Germany). Equal
amounts of protein were loaded onto 10% SDS-polyacrylamide gels and thereafter
blotted to an Immobilon-P membrane (Millipore, Bedford, MA). The blots were blocked
at 4°C overnight with 5% non-fat milk in TBST (500mM Tris, 54mM KCl, 2.74 M NaCl,
0.2% Tween-20) and subsequently incubated for 2 hr at room temperature with the
following primary antibodies: rabbit polyclonal antibodies against human Chmp1
(prepared and purified in our lab by Dr Natalia Belogortseva) (1 μl/ml), and stbm
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(prepared and purified by Dr Maiyon Park) (1 μl/ml). p53 (Cell Signaling) (1 μl/ml) and
phosphorylated-p53 (pp53) ser 37 (Cell Signaling) (1 μl/ml), Bad (Cell Signaling) (1
μl/ml) and Bak(Cell Signaling) (1 μl/ml). A mouse MAb against β-actin (abCam)
(0.1μl/ml) was used to confirm that the amounts of protein were equal. The blots were
incubated for 1 hr with horseradish-peroxidase-conjugated secondary antibodies.
Proteins were visualized by using enhanced chemiluminescent substrate detection for
HRP (Amersham, Buckinghamshire, England).

RNA Extraction and Microarray Analysis
Total cellular RNA was prepared from cells treated with ATRA for 1 day and cells
transfected with Chmp1 for 1 day using Tri Reagent (Sigma). In each case, cells were
disrupted and homogenized in the Tri Reagent. Chloroform was mixed with the lysate,
and the mixture was separated into three phases by centrifugation. The upper phase
which contained the RNA was collected and precipitated with isopropanol. The RNA
was used for Microarray experiment. Analysis of the results from microarray (microarray
experiment and analysis were done by Dr. Goran Boskovic of the Genomic Core, Joan
C. Edward School of Medicine, Marshall University) provided information on the level of
gene expression from cells treated with ATRA and cells transfected with Chmp1.
Differential expression of genes by microarray analysis was confirmed by Western-blot
assay.
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Statistical Analysis
All statistical analyses were performed with MINITAB statistical software (version 13) for
the Microsoft PC. Results on cell growth are expressed as mean ±SEM. Two-sample ttest was used to compare the equality of the means of DMSO (control) and ATRA, and
also between the means of CS2 (control) and Chmp1.
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RESULTS

Chmp1 represses growth of pancreatic tumor cells
We investigated the effect of Chmp1 expression on the growth of cancer cells by
transfecting CRL2151 cells with 5µg of Chmp1/ CS2 vector in a 10cm plate. Cells were
transfected with CS2 vector and Stbm/CS2 vector to serve as control. After 1, 2, 3 or 4
days of transfection, cells were counted and observed under Leica DMI6000B inverted
microscope attached to DFC camera for cell morphology.
Table 1 shows the effect of Chmp1 on the growth of CRL2151 cells. Chmp1
inhibits the growth of the cells all through the four days of transfection when compared
to the control (CS2 vector). However, there was no change in the morphology of the
cells (Figure 4).

Control
5

Chmp1
x105

Days of Transfection

x10

2

7.50±0.91

3.13±0.70

3

12.50±0.91

5.00±0.72

4

28.70±1.67

7.38±0.57

Table 1: Chmp1 induces growth inhibition in Chmp1 transfected pancreatic acinar cancer cells. CRL2151
cells were seeded at 8 x105 cells/ plate in a 10cm plate in DME High glucose medium with 10% FBS.
After incubation for 24hr cells were transfected (in triplicate) with Chmp1/CS2 and CS2 (control) vectors.
Cells were counted after 2, 3 and 4 days of transfection and average values from six counts were
obtained. The t-test analysis of the difference between the means of Chmp1 and CS2 (see appendix)
indicates a marked significant difference at 95% CI on each day, as p – values << 0.005.
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Control

Transfected

Day 1

Day 2

Day 3

Day 4

Figure 4: Chmp1 induces growth inhibition but no morphological changes in pancreatic acinar tumor cells.
CRL2151 cells were transfected with Chmp1/CS2 and CS2 (control) in 10cm plates for 1, 2, 3 and 4 days.
Cell density and morphology were observed using Leica DMI6000B inverted microscope attached to DFC
camera. Growth was inhibited in Chmp1 transfected cells (right) compared to CS2 transfected cells
(control) (left) but no morphological changes at day 1 - 4.
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Retinoic acid treatment induces the expression of Chmp1 and p53
To investigate the effect retinoic acid has on the growth of acinar carcinoma cells, we
counted CRL2151 cells and observed the cells under Leica DMI6000B inverted
microscope attached to DFC camera for cell morphology after treatment with ATRA. We
also performed Western blot analysis using antibodies which recognize Chmp1
(25kDa), p53 (53 kDa) and Stbm (75 kDa) to investigate the expression levels of these
proteins in the treated cells.
The growth curve of retinoic acid-treated cells showed no decrease in growth due
to retinoic acid treatment (Figure 5).
Observation of these cells under microscope did not show morphological
differences between the retinoic acid treated cells and the control treated cells (Figure
6). This is contrary to the earlier results obtained in our lab from similar treatment on
adinocarcinoma PanC-1 cells (Figure I). In this case, less growth was observed in
retinoic acid treated panC-1 cells. Observation of these PanC-1 cells under microscope
after four days of retinoic acid treatment showed less cell growth as well as
morphological changes.
Treatment of CRL2151 cells with retinoic acid however showed over-expression
of Chmp1 (4.5-fold) at day 1 compared to its expression in DMSO treated cells on the
same day (Figure 7). Chmp1 over-expression was accompanied by up-regulation of p53
(3.7-fold) at day 1. Similar expression of Chmp1 and p53 was observed in Panc-1 at
day 2 (Figures II & III). Even though stbm was over-expressed at day 4, there was no
accompanying up-regulation of p53 (Figure 7).
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7

Log No. of cells

6.5

6

5.5

DMSO
RA

5
Day 1

Day 2

Day 3

Day 4

Days of Treatment

Figure 5: Retinoic acid does not inhibit growth of pancreatic acinar tumor cells. CRL2151 cells were
seeded at 3 x105 cells/ plate in a 10cm plate in DME High glucose medium with 10% FBS. After
incubation for 24hr cells were treated with 20μM ATRA and DMSO (control) (in triplicate) for 1, 2, 3, and 4
days. Cells were counted after each period of treatment. Data represent the mean ± standard errors of
the mean (SE) from six counts. The t-test analysis of the difference between the means of DMSO and RA
(see appendix) indicates no significant difference at 95% CI on each day.

32

DMSO (Control)

ATRA

Day 1

Day 2

Day 3

Day 4

Figure 6: ATRA does not induce growth inhibition or morphology change in ATRA-treated pancreatic
acinar tumor cells. CRL2151 cells were seeded at 3 x105 cells/ plate in a 10cm plate in DME High glucose
medium with 10% FBS. After incubation for 24hr cells were treated with 20μM ATRA and DMSO (control)
(in triplicate) for 1, 2, 3, and 4 days. Cell density and morphology were observed using Leica DMI6000B
inverted microscope attached to DFC camera. There was no growth inhibition in ATRA-treated cells
(right) compared to DMSO treated cells (control) (left).No morphological changes at day 1 - 4.
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Fold difference of protein expression by
densitom etry analysis
5

Chmp1
p53
Stbm

4.5

Correction factors

4
3.5
3
2.5
2
1.5
1
0.5
0
1

2

3

4

Days

ATRA treatment

Figure 7: CRL 2151 cells were treated with ATRA(20μM) and DMSO(control) in a 10cm plate of DME
High glucose medium containing 10% FBS for 1, 2, 3 and 4 days. Cells were lysed, 5 micrograms of
protein were used for Western blot and immunodetection was done for Chmp1, p53 and Stbm. Graph
shows the expressions of Chmp1, p53 and Stbm corrected for β-actin and DMSO from densitometry
analysis.
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Chmp1 induces the expression of p53
CRL2151 cells were transfected with 5µg of Chmp1/ CS2 vector in a 10cm plate. Cells
were also transfected with CS2 vector and Stbm/CS2 vector to serve as control.
Western blot analysis was carried out using antibodies which recognize Chmp1
(25kDa), Stbm (73 kDa), p53 (53 kDa) and pp53 (ser 37, 53 kDa). Results showed that
the expression of Chmp1 was temporarily increased (3.7-fold) at day 1 in cells
transfected with Chmp1/CS2 vector (Figure 8). Chmp1 over-expression was
accompanied by p53 up regulation (3.3-fold) at day 1. This trend was followed by pp53
(ser 37) up-regulation (3.2-fold) at day 1 too. The low expression of Chmp1 at day 2 is
interesting, and may suggest that the expression of Chmp1 is repressed with time.
Results from PanC-1 cell line investigated in our lab did not show Chmp1 repression
with time. Even though Strabismus was up-regulated at day 1 and day 2 in Stbmtransfected cells, there was no effect on p53 and pp53 protein level. This result
demonstrates that p53 expression is specific to Chmp1 expression.

Protein expression in CRL2151 cells by microarray assay
To confirm that Chmp1 functions through retinoic acid by activating p53, microarray
analysis was performed on cells transfected with Chmp1 for 1 day and cells treated with
retinoic acid for 1 day. If Chmp1 functions through retinoic acid signaling we expect the
same genes to be up or down regulated when cells are treated with retinoic acid or
transfected with Chmp1. Table 2 shows few of same set of genes that were up or down
regulated. Of particular interest to us is the up-regulation of Bad and Bak which promote
apoptosis and the down regulation of cell cycle division associated proteins. Western lot
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assay confirmed the expression of Bad and Bak genes in cells transfected with
Chmp1/CS2 vector at day 2 and day 1 respectively (Figure 9).
Fold difference of protein expression
by densitom etry analysis
4

Chmp1
p53

3

pp53

2.5
2
1.5
1
0.5
0

Stbm

2.5
Correction factors

3.5
Correction factors

Fold difference of protein expression
by densitom etry analysis
3

p53
pp53

2
1.5
1
0.5
0

1

Days

Chmp1 transfection

2

1

Days

2

Stbm transfection

Figure 8: CRL 2151 cells were transfected with Chmp1/CS2, Stbm/CS2 and CS2 (control) vectors in a
10cm plate of DME High glucose medium containing 10% FBS for 1 and 2 days. Cells were lysed for
Western blot with immunodetection for Chmp1, p53, pp53 (ser37) and Stbm. Graphs show the
expressions of Chmp1, p53, pp53 and Stbm corrected for β-actin and CS2 from densitometry analysis.
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UP Regulated

Down Regulated
Function

Official

Gene

Symbol

ID

Bak1

12018

Name

Function

(Expression

Official

Gene

Fold)

Symbol

ID

Bcl2-

Proapoptotic

antagonist

(2)

Sfrs1

110809

Name

Fold)
Splicing factor,

Splicing of

arginine/serine-

pre-mRNA

rich1

(2)

BclBad

12015

(Expression

Overexpress

associated

Proapoptotic

death

(2)

Cdca7

66953

Cell division cycle

ed in human

associated 7

tumors (2.5)

promoter
Control of
Slc9a8

Prrx1

77031

18933

Solute carrier

intracellular

family

Regulation of
Rpl22

Ribosomal

protein

pH (2)

protein L22

synthesis (3)

Paired

Cranial

Von Hippel-

Tumor

related

development

Lindau binding

suppressor

homeobox1

(2)

protein 1

gene (2)

Vbp1

19934

22327

Tumor
Barx2

12023

BarH-like

Cellular

Oazin

homeobox2

differentiation

or Oazi

54375

(34)

Ornithine

inducer, cell

decarboxylase

growth and

antizyme inhibitor

division (2)

Heterogenous
Hnrpab

15384

nuclear

RNA splicing,

ribonucleo

transport (3)

protein A/B
Table 2: Microarray results of total mRNA from CRL 2151 cells transfected with Chmp1 for I day and cells
treated with ATRA for I day. After treatment with retinoic acid or transfection with Chmp1/CS2, RNA was
made using the Tri reagent. cDNA was generated and hybridized to agilent whole genome mouse 44k
array for analysis. Genes in the table are expressed in transfected and treated cells.
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Correction factors

9

Fold difference of protein expression by
densitom etry analysis

8

Bad

7

Bak

6
5
4
3
2
1
0
1

Day

2

Chmp1 transfection

Figure 9:

Chmp1 induces the expression of Bcl-2 family. CRL 2151 cells were transfected with

Chmp1/CS2, Stbm/CS2 and CS2 (control) vectors in a 10cm plate of DME High glucose medium
contining10% FBS for 1 and 2 days. Cells were lysed for Western blot with immunodetection for Bad and
Bak. Graph shows the expressions of Bad and Bak corrected for β-actin and CS2 from densitometry
analysis.
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DISCUSSION

The present study has led to a new finding about Chmp1 function in the suppression of
pancreatic tumor through the retinoic acid pathway. Chmp1 is thought to play a role in
the regulation of gene expression when located in the nucleus [2-4]. It was also
observed that when zebrafish embryos were microinjected with Chmp1, it induced
hyperplasia. On the basis of this observation and our results from the human cancer
profiling array for Chmp1, it is possible that Chmp1 may be involved in suppressing the
growth of tumor cells. We therefore hypothesized that Chmp1 may play a role in
inhibiting cell growth through retinoic acid signaling by activating p53. Protein p53 is
reported to be expressed and regulate cell growth and apoptosis during cancer cell
growth inhibition [35]. In this study we have shown that exogenous Chmp1 indeed
resulted in the inhibition of growth (Table 1) however, without any morphological change
of cells (Figure 4).
Retinoids are therapeutically used in the treatment of some cancers [31]. They
are reported to cause a decrease in the number of cells in pancreatic cancer [9, 16-17].
Results from our study did not show decrease in the growth of cells due to retinoic acid
treatment. This result is not surprising. A similar result was reported by Rosewicz et al
(1995), in which pancreatic acinar tumor cells did not show growth inhibition after
treatment with retinoids. Furthermore, Fujimoto et al (1999) reported that some
pancreatic tumor cell lines did not show growth inhibition when treated with retinoids.
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It is not known if Chmp1 expression is induced by retinoic acid treatment, nor
what function it may carryout if expressed. In this study, our result was able to show that
retinoic acid treatment induced the over-expression of Chmp1. This over-expression of
Chmp1 was accompanied by the up regulation of p53. Our further investigation showed
expression of Chmp1, p53 and pp53 (ser 37) to be up-regulated in cells transfected with
Chmp1 (Figure 8), accompanied by growth inhibition. Taken together, these results
suggest that Chmp1 inhibits cell growth by inducing the activation of p53 through RA
signaling pathway.
Strabismus, a binding partner of Chmp1 from the yeast 2-hybrid screening
carried out in our lab, was up-regulated at day 1 and day 2. However, it did not show
effect on p53 and pp53 protein level. This observation shows that even though
Strabismus functions in vertebrate extension movement, the induction of hyperplasia
and tumor suppression is rather specific to Chmp1 expression.
Microarray analysis of cells treated with ATRA and cells transfected with Chmp1
showed up-regulation of Bad and Bak (pro-apoptosis proteins), in addition to other
proteins up-regulated. Cell division cycle associated protein 7 (Cdca7) was among
proteins down-regulated. Cdca7 is frequently over-expressed in human cancers[74].
The down-regulation of Cdca7 and up-regulation of Bad and Bak in our study further
supports the suggestion that Chmp1 is involved in growth inhibition of CRL2151 cells,
consequently functioning in suppressing cancer growth.
In summary, the results from this study have shown that Chmp1 induces growth
inhibition in pancreatic tumor. Its expression is induced by retinoic acid in retinoic acid
treated pancreatic acinar tumor cells. Microarray analysis showed similar genes to be
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up or down regulated in cells treated with retinoic acid and cells transfected with
Chmp1.
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CHAPTER 4
CONCLUSIONS
1. Chmp1 was found to induce growth inhibition but no morphological changes when
CRL 2151 cells were transfected with Chmp1.
2. Over-expression of Chmp1 was induced in ATRA-treated cells accompanied by the
up-regulation of p53.
3. Chmp1 induced the up-regulation of p53 and also induced its stability by the upregulation of pp53-ser 37 in Chmp1-transfected CRL 2151 cells. Strabismus did not
show effect on p53 and pp53-ser 37 protein levels.
4. Similar proteins were up-regulated or down-regulated when CRL2151 cells were
treated with ATRA and transfected with Chmp1. Apoptotic agonists, Bad and Bak, were
among proteins up-regulated.
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FUTURE DIRECTIONS
Future direction on this study will focus on confirming other up and down regulated
genes from microarray analysis of cells transfected with Chmp1 and cells treated with
retinoic acid. This will include confirming Bad and Bak in RA treated cells.
Since our results showed that p53 and pp53 expression accompanied the
expression of Chmp1, investigating upstream proteins in p53 pathway (e.g. DNA-PK,
ATM) will provide information whether activated p53 induces growth arrest or apoptosis
or both during cell growth inhibition. This will be carried out by Western blot analysis of
lysate from CRL2151 cells transfected with Chmp1. Test for apoptosis will be done
using e.g. Tunel assay, Serine assay or Caspase detection assay.

Also Chmp1

transfection efficiency using the GFP cotransfection method will be determined.
We will further investigate the functions of Chmp1 by siRNA silencing of Chmp1
gene in CRL2151 cells. This will include studying the expression levels of p53 and pp53
after Chmp1 knock down in the cells.
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APPENDIX

Figure I: Treatment of panc-1 cells with ATRA (10μM) inhibits growth and results in morphology changes.
A- growth curve of panc-1 treated with ATRA. B- changes in cell morphology observed under Leica
inverted microscope attached to DFC camera. (Courtesy of Brandon Orr).
---■---■---■--- RA; ---♦---♦---♦--- DMSO
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Figure II: Western blot of panc-1 cells after treatment with 20μM ATRA. L- Low confluency. H- High
confluency (Courtesy of Brandon Orr).

Figure III: Western blot of panc-1 cells after treatment with 20μM ATRA (Courtesy of Brandon Orr).
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Raw data
Raw data table for ATRA treated growth curve.

Day1

Day1

Day2

Day2

Day3

Day3

Day4

Day4

Treatment

Day

DMSO

RA

DMSO

RA

DMSO

RA

DMSO

RA

Raw Data

2.50E+05

1.25E+05

5.00E+05

5.00E+05

7.00E+05

6.25E+05

2.00E+06

2.50E+06

2.20E+05

3.50E+05

2.75E+05

2.50E+05

1.00E+06

6.25E+05

2.50E+06

2.75E+06

3.75E+05

1.25E+05

3.75E+05

3.75E+05

5.00E+05

8.75E+05

2.63E+06

2.00E+06

2.50E+05

2.50E+05

6.75E+05

6.23E+05

8.75E+05

1.25E+06

2.25E+06

2.63E+06

2.50E+05

2.50E+05

1.25E+05

1.25E+05

8.75E+05

6.25E+05

3.13E+06

3.00E+06

1.25E+05

2.50E+05

3.75E+05

2.50E+05

1.38E+06

5.00E+05

3.63E+06

2.88E+06

Mean

2.45E+05

2.25E+05

3.88E+05

3.54E+05

8.88E+05

7.50E+05

2.69E+06

2.63E+06

Standard Error of the mean

3.27E+04

3.54E+04

7.69E+04

7.49E+04

1.21E+05

1.12E+05

2.43E+05

1.44E+05

Standard Deviation

8.00E+04

8.66E+04

1.88E+05

1.83E+05

2.95E+05

2.74E+05

5.96E+05

3.54E+05

6

6

6

6

6

6

6

6

Count
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Two-Sample T-Test for DMSO and RA (Day1)
DMSO
RA

N
Mean
6 245000
6 225000

StDev SE Mean
80000 32660
86603 35355

Difference = µ DMSO - µ RA
Estimate for difference: 20000
95% CI for difference: (-88882, 128882)
T-Test of difference = 0 (vs. not =): T-Value = 0.42 P-Value = 0.687 DF = 10

Two-Sample T-Test for DMSO and RA (Day2)
DMSO
RA

N
Mean StDev SE Mean
6 387500 188249 76852
6 353833 183407 74876

Difference = µ DMSO - µ RA
Estimate for difference: 33667
95% CI for difference: (-209056, 276389)
T-Test of difference = 0 (vs. not =): T-Value = 0.31 P-Value = 0.761 DF = 10

Two-Sample T-Test for DMSO and RA (Day3)
DMSO
RA

N
Mean
6 887500
6 750000

StDev SE Mean
295275 120546
273861 111803

Difference = µ DMSO - µ RA
Estimate for difference: 137500
95% CI for difference: (-234425, 509425)
T-Test of difference = 0 (vs. not =): T-Value = 0.84 P-Value = 0.425 DF = 10

Two-Sample T-Test for DMSO and RA (Day4)
DMSO
RA

N
Mean
6 2687500
6 2625000

StDev SE Mean
595556 243135
353553 144338

Difference = µ DMSO - µ RA
Estimate for difference: 62500
95% CI for difference: (-589524, 714524)
T-Test of difference = 0 (vs. not =): T-Value = 0.22 P-Value = 0.831 DF = 10
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Raw data
Raw data table for Chmp1 transfected growth curve.

Day

Day2

Day2

Day3

Day3

Day4

Day4

Vector

CS2

Chmp1

CS2

Chmp1

CS2

Chmp1

Raw data

6.25E+05

2.50E+05

1.38E+06

3.75E+05

3.50E+06

8.75E+05

3.75E+05

2.50E+05

1.13E+06

2.50E+05

2.88E+06

7.50E+05

7.50E+05

3.75E+05

8.75E+05

5.00E+05

2.88E+06

7.50E+05

8.75E+05

6.25E+05

1.25E+06

6.25E+05

2.38E+06

5.00E+05

8.75E+05

1.25E+05

1.38E+06

7.50E+05

3.10E+06

6.75E+05

1.00E+06

2.50E+05

1.50E+06

5.00E+05

2.50E+06

8.75E+05

Mean

7.50E+05

3.13E+05

1.25E+06

5.00E+05

2.87E+06

7.38E+05

Standard Error of the mean

9.13E+04

7.03E+04

9.13E+04

7.22E+04

1.67E+05

5.73E+04

Standard Deviation

2.24E+05

1.72E+05

2.24E+05

1.77E+05

4.08E+05

1.40E+05

Count

6

6

6

6

6

6
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Two-Sample T-Test for CS2 and Chmp1 (Day2)

CS2
Chmp1

N
Mean
6 750000
6 312500

StDev SE Mean
223607 91287
172301 70341

Difference = µ CS2 - µ Chmp1
Estimate for difference: 437500
95% CI for difference: (176799, 698201)
T-Test of difference = 0 (vs. not =): T-Value = 3.80 P-Value = 0.004 DF = 10

Two-Sample T-Test for CS2 and Chmp1 (Day3)

CS2
Chmp1

N
Mean StDev SE Mean
6 1252500 224182 91522
6 500000 176777 72169

Difference = µ CS2 - µ Chmp1
Estimate for difference: 752500
95% CI for difference: (488839, 1016161)
T-Test of difference = 0 (vs. not =): T-Value = 6.46 P-Value = 0.000 DF = 10

Two-Sample T-Test for CS2 and Chmp1 (Day4)

CS2
Chmp1

N
Mean StDev SE Mean
6 2873333 406678 166025
6 737500 140312 57282

Difference = µ CS2 - µ Chmp1
Estimate for difference: 2135833
95% CI for difference: (1705965, 2565702)
T-Test of difference = 0 (vs. not =): T-Value = 12.16 P-Value = 0.000 DF = 10
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Film properties report for Chmp1 (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: Chmp1

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Molecular weight: 25 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2
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Film properties report for Chmp1-βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.
Chmp1-Transfected
Adj. Vol. INT
Trf-Chmp
2149.88
5611.76
2905.17
2925.06
1619.69
735.05

Trf-Chmpactin
1409.27
982.58
2977.67
5940.36
7128.46
6746.6

TrfChmp(ratio)
1.525527401
5.711249975
0.975652104
0.492404501
0.227214574
0.108951175

Trf-Chmp(corr)
1
3.743787212
0.639550691
1
0.461438864
0.221263565
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Film properties report for Stbm (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: StbmN

Dilution: 1: 1000

Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Molecular weight: 75 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T
Medium: 5% milk in TBS-T
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Film properties report for Stbm- βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.
Strabismus-Transfected
Adj. Vol. INT
Trf-Stbm
Trf-Stbmactin
1337.14
15658.81
1928.95
14340.55
1531.08
7863.4
666.47
2578.45
917.46
6110.94
4729.11
6682.03

Trf-Stbm(ratio)
0.09
0.13
0.19
0.26
0.15
0.71

Trf-Stbm(corr)
1.0
1.6
2.3
1.0
0.6
2.7
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Film properties report for p53 (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: p53 (Cell Signaling)
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000
Dilution: 1: 1000

Molecular weight: 53 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Film properties report for p53- βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.
P53-Transfected
Adj. Vol. INT
Trf-p53
Trf-p53actin
4173.25
7083.78
8404.02
4309.6
3018.73
2802.82
2939.58
4804.18
2916.19
5010.87
3323.25
5365.64

Trf-p53(ratio)
0.59
1.95
1.07
0.61
0.58
0.62

Trf-p53(corr)
1.00
3.31
1.82
1.00
0.95
1.01
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Film properties report for phosphor p53- ser 37 (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: pp53-ser 37 (Cell Signaling) Dilution: 1: 1000 Medium: 5% milk in TBS-T
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Molecular weight: 53 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T
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Film properties report for pp53 ser37-βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.
Pp53 (ser 37)-Transfected
Adj. Vol. INT
Trf-ser37
Trf-ser37-actin
4713.86
1409.27
10634.81
982.58
7871.56
2977.67
11386.88
5940.36
13476.64
7128.46
12789.99
6746.6

Trf-ser37(ratio)
3.344894875
10.82335281
2.643530008
1.916866991
1.890540173
1.895768239

Trf-ser37(corr)
1
3.235782651
0.790317815
1
0.986265704
0.988993106
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Film properties report for Chmp1 (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: Chmp1

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Molecular weight: 25 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day1
Lane 3: DMSO Day1
Lane 4: RA Day2
Lane 5: DMSO Day2
Lane 6: RA Day3
Lane 7: DMSO Day3
Lane 8: RA Day4
Lane 9: DMSO Day4
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Film properties report for Chmp1-βactin (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day1
Lane 3: DMSO Day1
Lane 4: RA Day2
Lane 5: DMSO Day2
Lane 6: RA Day3
Lane 7: DMSO Day3
Lane 8: RA Day4
Lane 9: DMSO Day4

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.
Chmp1-ATRA treated
Adj. Vol. INT
Trd-Chmp
Trd-Chmp-actin
2056.11
14398.49
7115.64
11045.35
2535.09
13516.78
799.37
11778.02
372.59
13409.67
1563.17
13207.32
2785.21
16080.38
3593.7
16593.57

Trd-Chmp(ratio)
0.142800391
0.644220419
0.187551325
0.067869642
0.027785173
0.118356336
0.173205484
0.216571841

Trd-Chmp(corr)
1.0
4.5
1.0
0.4
1.0
4.3
1.0
1.3
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Film properties report for Stbm (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: StbmN
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Dilution: 1: 1000

Molecular weight: 75 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day2
Lane 3: DMSO Day2
Lane 4: RA Day3
Lane 5: DMSO Day3
Lane 6: RA Day4
Lane 7: DMSO Day4

Medium: 5% milk in TBS-T
Medium: 5% milk in TBS-T
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Film properties report for Stbm - βactin (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day2
Lane 3: DMSO Day2
Lane 4: RA Day3
Lane 5: DMSO Day3
Lane 6: RA Day4
Lane 7: DMSO Day4

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.

Strabismus-ATRA treated

Adj. Vol. INT
Trd-Stbm
Trd-Stbmactin
3533.43
16231.67
5728.83
17223.41
645.07
17457.64
1458.15
18362.55
811.84
21005.89
2984.38
16673.09

Trd-Stbm(ratio)
0.217687398
0.332618802
0.036950584
0.079408906
0.038648208
0.178993816

Trd-Stbm(corr)
1.0
1.5
1.0
2.1
1.0
4.6
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Film properties report for p53 (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: p53 (Cell Signaling)
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000
Dilution: 1: 1000

Molecular weight: 53 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day1
Lane 3: DMSO Day1
Lane 4: RA Day2
Lane 5: DMSO Day2
Lane 6: RA Day3
Lane 7: DMSO Day3
Lane 8: RA Day4
Lane 9: DMSO Day4

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Film properties report for p53- βactin (ATRA treated)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)

Dilution: 1: 10000

Medium: 5% milk in TBS-T

Secondary Antibody: Anti Rabbit

Dilution: 1: 10000

Medium: 5% milk in TBS-T

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: RA Day1
Lane 3: DMSO Day1
Lane 4: RA Day2
Lane 5: DMSO Day2
Lane 6: RA Day3
Lane 7: DMSO Day3
Lane 8: RA Day4
Lane 9: DMSO Day4
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Raw data table produced from spot densitometry of Western blot films.

p53-ATRA treated

Adj. Vol. INT
Trd-p53
Trd-p53actin
1794.39
14398.49
5120.17
11045.35
3065.98
13516.78
2802.92
11778.02
2292.13
13409.67
2903.23
13207.32
3582.19
16080.38
4262.39
16593.57

Trd-p53(ratio)
0.12462348
0.46355887
0.22682769
0.23797888
0.17093113
0.21981977
0.22276775
0.25686998

Trd-p53(corr)
1.0
3.7
1.0
1.0
1.0
1.3
1.0
1.2
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Film properties report for BAD (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: BAD (Cell Signaling)
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Molecular weight: 23 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Film properties report for BAD- βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T

77

Raw data table produced from spot densitometry of Western blot films.

Bad-Transfected

Adj. Vol. INT
Trf-Bad Trf-Badactin
0
12592.14
0.4588
9495.77
0
6162.74
1780.23
8879
9472.59
6137.55
8651.35
3726.98

Trf-Bad(ratio)
0
4.83163E-05
0
0.20049893
1.543382946
2.321276208

Trf-Bad(corr)
0.0
0.0
0.0
1.0
7.7
11.6
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Film properties report for BAK (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: BAD (Cell Signaling)
Secondary Antibody: Anti Rabbit

Dilution: 1: 1000

Molecular weight: 25 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Dilution: 1: 1000

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T

79

Film properties report for BAK- βactin (transfected)
Cell type: CRL 2151

Protein quantity: 5μg

Gel type: 10% Tris-HCL SDSPAGE

Electrophoresis Voltage: 100V

Transfer Voltage: 100V

Duration: 45min

Primary Antibody: β-actin (abCam)
Secondary Antibody: Anti Mouse

Dilution: 1: 10000
Dilution: 1: 10000

Molecular weight: 42 kDa
Lane 1: ProSieve color protein marker 5μl
Lane 2: CS2 Day1
Lane 3: Chmp1 Day1
Lane 4: Stbm Day1
Lane 5: CS2 Day2
Lane 6: Chmp1 Day2
Lane 7: Stbm Day2

Medium: 5% milk in TBS-T

Medium: 5% milk in TBS-T
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Raw data table produced from spot densitometry of Western blot films.

Bak-Transfected

Adj. Vol. INT
Trf-Bak
Trf-Bak-actin
2324.67
11910.45
5273.09
10221.44
4044.86
9292.91
1190.51
12478.32
698.66
14475.16
1711.21
11878.11

Trf-Bak(ratio)
0.19517902
0.51588524
0.43526301
0.09540627
0.04826613
0.14406417

Trf-Bak(corr)
1.0
2.6
2.2
1.0
0.5
1.5
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